Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Amnesia01:13

Amnesia

324
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
324
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

647
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
647

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alzheimer's disease.

Lancet (London, England)·2026
Same author

Retinal biomarkers for early Alzheimer's detection: a systematic review of optical coherence tomography (OCT) findings.

BMJ open ophthalmology·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Alzheimer's Imaging Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative.

Alzheimer's research & therapy·2025
Same author

Detection of triboelectric discharges during dust events on Mars.

Nature·2025

Related Experiment Video

Updated: Dec 12, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K

Does amnesia specifically predict Alzheimer's pathology? A neuropathological study.

Maxime Bertoux1, Pascaline Cassagnaud2, Thibaud Lebouvier3

  • 1Univ Lille, Lille Neuroscience & Cognition (Inserm UMRS1172) Degenerative and Vascular Cognitive Disorders, CHU Lille, Laboratory of Excellence Distalz (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.

Neurobiology of Aging
|August 16, 2020
PubMed
Summary
This summary is machine-generated.

Amnesia is not a reliable predictor of Alzheimer's disease (AD). Many patients with AD pathology showed no amnesia, while many without AD pathology did, challenging its diagnostic specificity.

Keywords:
AD pathologyAlzheimer’s diseaseAmnesiaFCSRTFree and cuedMemory

More Related Videos

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

3.8K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.2K

Related Experiment Videos

Last Updated: Dec 12, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

3.8K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.2K

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Amnesia is a hallmark symptom of Alzheimer's disease (AD), crucial for clinical diagnosis.
  • Recent studies question the specificity of amnesia as an early indicator of AD.

Purpose of the Study:

  • To investigate the predictive value of amnesia for Alzheimer's disease (AD) pathology.
  • To assess the accuracy of memory assessments in diagnosing AD in early cognitive decline.

Main Methods:

  • Clinicopathological study of 91 patients with early cognitive decline.
  • Free and cued verbal memory assessments administered during early cognitive decline.
  • Autopsy-confirmed histological diagnoses (pure AD, mixed AD, non-AD pathologies).
  • Data-driven automated classification to correlate memory performance with pathology.

Main Results:

  • Three performance clusters identified, indicating varying levels of amnesia.
  • Low correspondence found between amnesia clusters and AD pathology.
  • Approximately one-third of patients with AD pathology were non-amnesic at presentation.
  • Around 45% of patients without AD pathology exhibited amnesia.
  • Data-driven prediction of AD pathology based on memory performance showed poor accuracy.

Conclusions:

  • Free and cued memory assessments effectively diagnose amnesic syndromes.
  • These memory assessments lack the accuracy to reliably predict Alzheimer's disease (AD) pathology.
  • The diagnostic specificity of amnesia for AD requires re-evaluation.